FDA fast-tracks Abbvie's lung cancer drug

The investigational drug against non-small cell lung cancer can look forward to special treatment by the FDA, which has granted the drug Breakthrough Therapy Designation.
Photo: Abbvie / PR
Photo: Abbvie / PR
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen

Abbvie starts out 2022 with positive news, as the US Food and Drug Administration (FDA) sees big potential in Abbvie's investigational antibody-drug conjugate, telisotuzumab vedotin.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading